Cross-program efficacy summary

This page is a conservative derived read across the current local source stack. It is meant to answer a practical question: which programs currently have the clearest public efficacy story, and which still look early, thin, or weak?

• Shared comparison page now live: Cross-program longitudinal UAS7 comparison
• Program-specific plotted page: Remibrutinib longitudinal UAS7
• Program-specific plotted page: Barzolvolimab longitudinal UAS7
• Program-specific plotted page: Rilzabrutinib longitudinal UAS7

Quick read

• Current flagship CSU efficacy pages: remibrutinib and barzolvolimab.
• Most mature oral BTK CSU story: remibrutinib.
• Deepest KIT sponsor-poster durability/subgroup story: barzolvolimab.
• Current plotted longitudinal pages: remibrutinib, barzolvolimab, and rilzabrutinib, plus a shared cross-program comparison page.
• Meaningful but shallower Phase 2 CSU story: rilzabrutinib, now with a landmark-based plotted page but still a thinner numeric time-series layer than the two flagship programs.
• Earlier proof-of-concept / mechanism layer: EVO756 and SEP-631.
• Currently weak or immature public efficacy layer: EP262, BLU-808, and other thin public programs.

Program-by-program notes

Remibrutinib

• Current read: Richest BTK CSU package in the vault, spanning phase 2b signal, pivotal phase 3 confirmation, and 52-week follow-up.
• Evidence type: Primarily manuscript-backed, with sponsor support for topline framing and CIndU expansion
• Why this matters:
• Phase 2b and REMIX phase 3 manuscripts together support rapid symptom reduction, clear week-12 efficacy, and sustained benefit through week 52.
• Sponsor press releases add useful topline framing around rapid onset, durability, and the newer CIndU expansion without replacing the manuscript-backed CSU core.
• Current local read: the most mature oral BTK urticaria efficacy story in the vault.
• Key local pages: wiki/programs/remibrutinib.md; wiki/trials/remibrutinib-nct03926611-phase-2b.md

Barzolvolimab

• Current read: Deep KIT-sponsored CSU efficacy package with manuscript-backed phase 2 activity and unusually rich sponsor-poster durability follow-up.
• Evidence type: Manuscript-backed plus deep sponsor-poster layer
• Why this matters:
• Phase 2 CSU evidence is no longer just a week-12 story: the local sponsor layer extends into week-52 control, patient-reported disease control, and post-treatment follow-up framing.
• The newly cached EADV 2025 poster supports similar activity in low-IgE and normal/high-IgE subgroups, which matters strategically because low-IgE CSU is often discussed as a harder-to-treat biology.
• Current local read: one of the strongest public non-BTK CSU efficacy packages in the vault, with clearer durability and subgroup texture than most peers.
• Key local pages: wiki/programs/barzolvolimab.md; wiki/trials/barzolvolimab-nct05368285.md

Rilzabrutinib

• Current read: Credible Phase 2 CSU signal with early itch improvement, but still shallower and less mature than remibrutinib or barzolvolimab.
• Evidence type: Phase 2 manuscript plus sponsor press release/poster support
• Why this matters:
• The local stack supports week-12 ISS7, UAS7, and HSS7 improvement in RILECSU, with week-1 itch signal visible in sponsor materials.
• Evidence remains phase-2-weighted and sponsor/manuscript coverage is narrower than the two flagship programs.
• Key local pages: wiki/programs/rilzabrutinib.md; wiki/trials/rilzabrutinib-nct05107115.md

Fenebrutinib

• Current read: Historical BTK efficacy signal exists, but the current local layer is still thinner and less operationally useful than remibrutinib.
• Evidence type: Publication-backed historical competitor layer
• Why this matters:
• Useful as a competitor/historical comparator, but not the flagship efficacy story in this vault.
• Key local pages: wiki/programs/fenebrutinib.md

EVO756

• Current read: Mechanistic and proof-of-concept signal is visible, but mature CSU efficacy still sits below the flagship programs.
• Evidence type: Mostly sponsor-sourced early program evidence
• Why this matters:
• Sponsor-backed healthy-volunteer and early urticaria program materials support target engagement and proof-of-concept logic.
• Current local read: promising but earlier and less clinically mature than the leading CSU programs.
• Key local pages: wiki/programs/evo756.md

SEP-631

• Current read: Strong mechanistic wheal-inhibition signal, but no mature public CSU efficacy package yet in the local layer.
• Evidence type: Sponsor-poster proof-of-mechanism data
• Why this matters:
• The AAAAI 2026 poster supports proof-of-mechanism and once-daily oral development logic.
• Current local read: intriguing early mechanism story, not yet a mature clinical-efficacy competitor in public data.
• Key local pages: wiki/programs/sep-631.md

EP262

• Current read: Current local public result layer is unfavorable after posted CT.gov phase 2 results failed to separate from placebo.
• Evidence type: CT.gov posted results with negative topline read
• Why this matters:
• The active-versus-placebo signal does not currently support a strong efficacy narrative in the vault.
• Key local pages: wiki/trials/ep262-nct06077773.md

BLU-808

• Current read: Mechanism and ownership context are clearer now, but mature urticaria efficacy remains thin in the current public source stack.
• Evidence type: Program-tracking layer only
• Why this matters:
• Current local value is mostly program tracking and source capture rather than efficacy interpretation.
• Key local pages: wiki/programs/blu-808.md